How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Two solid-value approaches, one well-built ETF. Our research team assigns Gold ratings to strategies that they have the most conviction will outperform their Morningstar Category average over a market ...

How do you get from a chatbot that sometimes makes things up to a machine that humans might struggle to control? There are several steps in that argument, and plenty of uncertainty. But an idea known ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Regan Peng is an AI founder and former senior tech executive, focused on personal AI, ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

“Recursive self-improvement” is the idea that artificial intelligence could learn to build and train itself, creating exponential new progress — and risk. Jeff Clune, a computer scientist and ...

Recursion Pharmaceuticals reported 5 insider transactions totaling $528,153.30. Activity split between 3 Tax Payments worth $351,830.92 and 2 Sales worth $176,322.38. Ben R Taylor and Najat Khan ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...